Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000143

Drug Information
SynonymsNCGC00179672-01; 38304-91-5; Bio2_000585; EU-0100786; Prestwick_521; SMR000326812; KBio1_000160; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; Minossidile [Italian]; SAM002589949; DivK1c_000160; SGCUT00112; MLS000028566; MINOXIDIL (FOR WOMEN); Spectrum4_000063; KBio2_002673; Spectrum3_000509; Rogaine for Men; Rogaine for Women; Bio2_000105; AC1L1HN1; Theroxidil; SPECTRUM1500415; nchembio.79-comp10; CHEMBL609587; Minoximen; LS-135040; Riup (TN); Spectrum_000969; NCGC00024666-01; MINOXIDIL (FOR MEN); CPD000058963; KBioGR_000585; S1383_Selleck; BRN 0886240; NCGC00024666-05; HMS2091F20; NCGC00018278-01; ZINC00001735; NCGC00015673-04; Rogaine Extra Strength for Men; Loniten; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; SPBio_001006; SPBio_001980; CHEBI:49774; Rogaine; KBio3_000210; to_000070; Minoxidil (USP/INN); Bio1_001062; MolPort-003-666-236; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; KBio2_004017; 5-25-12-00317 (Beilstein Handbook Reference); AB00513797; BPBio1_000065; NCGC00015673-02; C9H15N5.H2O; HMS1920P03; Pfizer Brand of Minoxidil; Normoxidil; Prestwick3_000020; Prestwick0_000020; Alostil; Spectrum5_001299; Minoxigaine; CAS-38304-91-5; HMS1989F07; Prexidil; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; Gen-Minoxidil; NCGC00024666-02; minoxidil; KBio2_005241; Spectrum2_001053; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; Bio1_000573; Men's Rogaine; Tocris-0583; KBio3_000209; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; D00418; NCGC00024666-06; SMR000058963; Minoxidil Pfizer Brand; DB00350; CHEMBL802; HMS1361F07; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; NCGC00015673-01; MLS001077294; Lopac0_000786; BSPBio_002037; Neoxidil; KBio3_001537; KBio2_000105; Tricoxidil; Bio1_000084; Minoxidil [USAN:BAN:INN]; HMS2089L08; EINECS 253-874-2; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; SBB056986; KBioGR_000105; NCGC00015673-11; Alopexil; Regaine; M1389; 16317-69-4; NCGC00024666-07; BCBcMAP01_000193; CPD-7668; ROGAINE EXTRA STRENGTH (FOR MEN); TM-160; NCGC00024666-03; HMS1791F07; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; Pierminox; CHEBI:6942; Mens Rogaine Foam; MINOXIDIL EXTRA STRENGTH (FOR MEN); Men s Rogaine Foam; AC-5271; NCGC00024666-08; U-10858; MLS000859953; ROGAINE (FOR WOMEN); RiUP; KBioSS_001449; Prestwick1_000020; D008914; BRD-K14888893-001-02-3; NINDS_000160; BSPBio_000059; BSPBio_001385; HMS500H22; HMS1568C21; DB08225; HSDB 6538; Jsp006715; Rogaine, Regaine, Avacor and Mintop, Minoxidil; KBio2_001449; Minoxidilum [INN-Latin]; M 4145; NCGC00024666-04; IDI1_033855; Minossidile; U-10,858; KBioSS_000105; Prestwick2_000020; Trocoxidil; CID4201; Lopac-M-4145; Apo-Gain; MINOXIDIL EXTRA STRENGTH FOR MEN; KBio2_006585; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; IDI1_000160; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; BRD-K06902185-001-05-2; MolPort-005-932-694; Minoxidilum; CBiol_001798; Rogaine (TN); Lonolox; SMP1_000192; ROGAINE (FOR MEN); Ambap38304-91-5; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; Minodyl; Loniten (TN); U 10858
Trade NameRogaine; Regaine
CompanyUpjohn Corporation
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESC1CCN(CC1)C2=NC(=N)N(C(=C2)N)O    
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 38304-91-5
PubChem Compound IDCID 4201.
PubChem Substance IDSID 179263.
SuperDrug ATC IDC02DC01; D11AX01
SuperDrug CAS ID038304915;
TargetATP-sensitive potassium channelOpener[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071344 To Reference
Ref 2Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600. To Reference
Ref 3Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998 Jun;34(6):457-82. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543